The Molecular Cascade of Cancer: Initiation, Promotion, and Where Prevention Actually Works

In the previous essay I described the conceptual distinction between tumors and cancer — what makes a mass of abnormal cells malignant rather than merely aberrant. Here I want to go one level deeper: into the molecular events that convert a normal cell into a malignant one, and why understanding those events matters clinically for anyone thinking seriously about cancer prevention.

This is not academic oncology for its own sake. Every step in the carcinogenesis cascade represents a window in which the process can be interrupted — or accelerated. Knowing where those windows are changes how I advise patients.

The First Requirement: Non-Lethal Genetic Damage

The foundational constraint of carcinogenesis is one that is rarely emphasized in popular cancer discussions: the mutation must be survivable. A cell that sustains catastrophic DNA damage typically dies — either through apoptosis triggered by its own surveillance mechanisms, or through necrosis. Cancer cannot arise from a dead cell.

What carcinogenesis requires is damage that is significant enough to alter the cell’s regulatory behavior but not so severe as to activate the cell’s death programs. This is a narrow window, and it helps explain why cancer is simultaneously common and — from the perspective of any individual mutation — relatively rare. Most mutations are either repaired, produce lethal cellular dysfunction, or occur in non-critical genomic regions. The subset that hit proto-oncogenes or tumor suppressor genes in ways that produce heritable behavioral changes without triggering immediate cell death is the subset that initiates carcinogenesis.

The agents that produce this calibrated damage are diverse: certain chemical carcinogens, ionizing radiation, oncogenic viruses, and — increasingly recognized — the endogenous DNA damage produced by chronic oxidative stress, inflammation, and metabolic dysregulation. The last category is the one most directly modified by lifestyle.

Initiation: The Point of No Return That Isn’t

Initiation refers to the acquisition of the first driver mutation — the permanent, heritable genetic change that sets a cell on the carcinogenic trajectory. Once a cell is initiated, that change persists in all its daughter cells. In this sense, initiation is irreversible.

But irreversibility at the cellular level does not mean inevitable cancer at the organismal level. An initiated cell that never encounters the conditions that drive promotion may remain clinically silent for a lifetime. The genome of every adult human almost certainly contains initiated cells — this is the inevitable product of decades of cellular replication in an environment that includes carcinogenic exposures, chronic inflammation, and the background error rate of DNA replication itself.

What determines whether an initiated cell progresses is what happens next — in the promotion phase.

Promotion: Where Prevention Has the Most Leverage

Promotion is the phase in which initiated cells undergo clonal expansion — selective proliferation that produces a population of cells carrying the initiating mutation. Critically, promotion does not require additional genetic damage. It requires a cellular environment in which the initiated cells have a growth advantage over their normal neighbors.

This environment is created by promoters: agents and conditions that stimulate cell division, suppress apoptosis, or create inflammatory microenvironments that favor mutant cell survival. Chronic estrogen exposure is a promoter in breast and endometrial carcinogenesis. Chronic bile acid exposure is a promoter in colorectal carcinogenesis. Chronic hepatitis B and C infection creates the inflammatory environment that promotes hepatocellular carcinoma. And — of broad relevance to lifestyle medicine — the metabolic syndrome cluster of chronic hyperinsulinemia, elevated IGF-1, central adiposity, and systemic inflammation functions as a promoter across multiple cancer types simultaneously.

The clinical importance of this phase is that promotion is reversible. Remove the promoter, and clonal expansion decelerates or stops. This is the biological basis for the observed reduction in cancer risk with lifestyle modification, hormonal regulation, anti-inflammatory interventions, and constitutional treatment — they do not undo initiation, but they remove or attenuate the promotional environment that converts initiated cells into expanding clones.

The Oncogene-Suppressor Balance

At the molecular level, carcinogenesis involves the disruption of the normal push-pull relationship between proto-oncogenes and tumor suppressor genes.

Proto-oncogenes encode proteins that promote cell division, survival, and growth — they are normal cellular components that become problematic when mutated into constitutively active forms (oncogenes). RAS mutations, found in approximately 30% of human cancers, are a canonical example: the mutant RAS protein is locked in the active, growth-promoting configuration regardless of upstream signals. The cellular accelerator is stuck in the pressed position.

Tumor suppressor genes encode proteins that constrain cell division and promote apoptosis when cellular damage is detected. p53, the most commonly mutated gene in human cancer, is the master regulator of the cellular response to DNA damage — when functioning normally, it halts the cell cycle to allow repair or triggers apoptosis when repair is not possible. When p53 is lost, cells with significant DNA damage continue dividing rather than dying, accumulating additional mutations with each cycle. The brake has been removed.

Full malignant transformation requires both: gain-of-function in at least one oncogene and loss-of-function in at least one tumor suppressor. This two-hit requirement, combined with the multiple redundant suppressor systems in normal cells, explains why cancer typically takes decades to develop — enough mutations must accumulate in the right genes to overwhelm the multiple layers of cellular protection.

Progression and the Acquisition of Hallmarks

Progression is the phase in which the expanding clone acquires the additional capabilities that define fully malignant behavior: sustained angiogenesis (the ability to recruit a blood supply), invasion of adjacent tissue, and ultimately metastasis. These capabilities are not present in the initiating mutation — they are acquired through the additional genetic instability that characterizes the promotion phase, where rapid cell division with impaired repair mechanisms generates new mutations at an accelerated rate.

The therapeutic implication of this phase is that cancer becomes progressively more difficult to treat as progression advances, because each additional mutation expands the genomic diversity of the tumor population and increases the probability that drug-resistant variants already exist within the clone. Early detection — identifying cancer in the transition from promotion to early progression — is clinically valuable precisely because the degree of genomic complexity is still relatively limited.

Where Constitutional Medicine Intervenes

From a Korean medicine perspective, the carcinogenesis cascade maps onto recognizable constitutional patterns at each phase. The oxidative and inflammatory environment that produces initiating mutations correlates with chronic Qi and Blood stagnation — the pathological accumulation that I described in the previous essay as the classical Korean medicine predisposition to malignancy. The promotional environment of hyperinsulinemia, chronic inflammation, and immune suppression corresponds to the combined pattern of Phlegm-Damp accumulation and Qi deficiency that is the constitutional backdrop of most patients who develop solid tumors after the sixth decade.

Constitutional treatment does not reverse initiation. But targeted intervention in the promotional environment — reducing inflammatory burden, correcting metabolic dysregulation, restoring immunological surveillance — directly addresses the conditions under which initiated cells expand into clinically significant tumors. This is not an alternative to conventional cancer treatment. It is the appropriate domain of preventive medicine, operating at the molecular phase where prevention is most biologically tractable.

This article reflects the clinical observations and teaching practice of Professor Seungho Baek, Professor of Korean Medicine at Dongguk University College of Korean Medicine, specializing in Pathology and Oncology.